Development of a model of ischemic heart disease using cardiomyocytes differentiated from human induced pluripotent stem cells by Wei, Heng et al.
lable at ScienceDirect
Biochemical and Biophysical Research Communications 520 (2019) 600e605Contents lists avaiBiochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate/ybbrcDevelopment of a model of ischemic heart disease using
cardiomyocytes differentiated from human induced pluripotent stem
cells
Heng Wei a, b, Chen Wang a, Rui Guo a, c, Ken Takahashi a, *, Keiji Naruse a
a Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho,
Kita-ku, Okayama, 700-8558, Japan
b Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University, Kyoto, 606-8501, Japan
c Department of Cardiac Surgery, Peking University Third Hospital, Beijing, 100191, Chinaa r t i c l e i n f o
Article history:
Received 24 August 2019
Accepted 27 September 2019
Available online 14 October 2019
Keywords:
Ischemic heart disease
Myocardial infarction
Human induced pluripotent stem cells
Cardiomyocytes* Corresponding author.
E-mail address: takah-k2@okayama-u.ac.jp (K. Tak
https://doi.org/10.1016/j.bbrc.2019.09.119
0006-291X/© 2019 The Authors. Published by Elseviera b s t r a c t
Ischemic heart disease remains the largest cause of death worldwide. Accordingly, many researchers
have sought curative options, often using laboratory animal models such as rodents. However, the
physiology of the human heart differs signiﬁcantly from that of the rodent heart. In this study, we
developed a model of ischemic heart disease using cardiomyocytes differentiated from human induced
pluripotent stem cells (hiPS-CMs). After optimizing the conditions of ischemia, including the concen-
tration of oxygen and duration of application, we evaluated the consequent damage to hiPS-CMs.
Notably, exposure to 2% oxygen, 0mg/ml glucose, and 0% fetal bovine serum increased the percentage
of nuclei stained with propidium iodide, an indicator of membrane damage, and decreased cellular
viability. These conditions also decreased the contractility of hiPS-CMs. Furthermore, ischemic condi-
tioning increased the mRNA expression of IL-8, consistent with observed conditions in the in vivo heart.
Taken together, these ﬁndings suggest that our hiPS-CM-based model can provide a useful platform for
human ischemic heart disease research.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ischemic heart disease, deﬁned as the occlusion of the coronary
artery by intravascular plaque that has accumulated over time or
acute embolizationwith thrombus, remains the single largest cause
of death worldwide despite decreasing rates in most countries [1].
Accordingly, several basic studies of laboratory animal models have
been conducted to address this problem. However, animal model-
based approaches are associated with ethical, technical, and aca-
demic problems. Particularly, animal ethics requires the minimi-
zation of animal sacriﬁce. Moreover, such studies often use
occlusion of the anterior descending branch of left coronary artery
as a model of ischemic heart disease [2], which requires a high level
of skill with microsurgery to produce reproducible data, particu-
larly in rodents. Moreover, various physiological aspects of the
human heart, such as the heart rate and action potential formation
[3], are different from those in rodents.ahashi).
Inc. This is an open access article uThe above-mentioned problems can be resolved by using car-
diomyocytes derived from human stem cells, such as induced
pluripotent stem (iPS) cells. Such an approach avoids the sacriﬁce of
animals and performance of technically difﬁcult surgical proced-
ures. Furthermore, cardiomyocytes differentiated from human iPS
cells not only recapitulate the physiology of the human heart, but
are also expected to reﬂect the sensitivity of the donor cells to
various drugs. In this study, a pilot experiment with the rat car-
diomyocyte cell line, H9c2, led us to establish a model of ischemic
heart disease using cardiomyocytes derived from human iPS cells
(hiPS-CMs). In our model, oxygen and glucose deprivation led to
decreases in hiPS-CM contractility and viability. Our ﬁndings sug-
gest that our new model will provide a useful platform for human
ischemic heart disease research.2. Materials and methods
2.1. H9c2 culture
H9c2 rat cardiomyocytes (ATCC, Manassas, VA, USA) werender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with 10% fetal calf serum. The cells were plated in 96-well plates at
a density of 3 104 cells/well.
2.2. iPS culture
The procedure used to maintain iPS cells has been described
elsewhere [4]. We used this procedure with slight modiﬁcations.
Brieﬂy, human iPS cells (201B7 cell; RIKEN, Tsukuba, Japan) were
cultured in StemFit AK02N medium (Ajinomoto, Tokyo, Japan) on
6-well culture plates coated with laminin (iMatrix-511, Nippi,
Tokyo, Japan). Prior to coating, iMatrix-511 was diluted to 0.5 mg/ml
in phosphate-buffered saline (PBS) and added to the plates at a total
volume of 2.0 ml/well, followed by incubation at 37 C for 30min.
After coating and removal of the iMatrix-511 solution, the iPS cells
were seeded at a density of 3 104 cells/well. Human iPS cells were
passaged in accordance with the protocol supplied by the manu-
facturer of the medium.
2.3. Induction of cardiac differentiation of iPS cells
Cells were differentiated in 96-well plates. First, iMatrix-511was
diluted to 1.675 mg/ml with PBS and added towells in aliquots of 0.1
ml/well, followed by an incubation at 37 C for 30min. Subse-
quently, iPS cells were seeded onto feederless 96-well plates at a
density of 3.0 104 cells/well. One day later, the cells were cultured
in Essential 8 Medium (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) for 3 days, and the medium was changed every day (Fig. 1A).
Subsequently, iPS cell differentiation was initiated using PSC Car-
diomyocyte Differentiation Kits (Thermo Fisher Scientiﬁc) in
accordance with the manufacturer’s instructions. Brieﬂy, the spent
medium was aspirated and slowly replaced with pre-warmed
Cardiomyocyte Differentiation Medium A. Two days later, theFig. 1. Nutrients and oxygen deprivation induce damage in H9c2 rat cardiomyocytes. (A) Cel
glucose (Glu, 2mg/ml), and/or oxygen (O2, 21%). The statistical comparison relative to th
Bonferroni post-hoc test. (B) Microscopic image of propidium iodide (PI)-stained nuclei (red
and ischemic (FBS, Glu, and O2) conditions were compared. Scale bar: 100 mm. (C) M
Ischemic cells exhibited a decrease in forward scatter intensity (D) and increase in PI staining
to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)medium was aspirated and slowly replaced with pre-warmed
Cardiomyocyte Differentiation Medium B. After another 2-day in-
cubation, the medium was replaced with pre-warmed Car-
diomyocyte Maintenance Medium. Subsequently, the cells were
incubated in a CO2 incubator at 37 C, and Cardiomyocyte Mainte-
nance Medium was replaced every other day up to Day 30.
2.4. Exposure to hypoxia
Cells were exposed to an incubator infused with nitrogen gas to
control the internal oxygen concentration at 2%.
2.5. Immunostaining
Immunocytochemistry was used to evaluate the expression of a
cardiac marker, TNNT2. Prior to immunoﬂuorescence staining, the
cells were ﬁxed with 4% paraformaldehyde in PBS (Wako, Osaka,
Japan) for 10min at room temperature and washed three times
with PBS. Subsequently, the cells were permeabilized with 0.2%
Triton X-100 (Nacalai Tesque, Kyoto, Japan) for 15min and blocked
with 3% bovine serum albumin (BSA; A9418, Sigma Aldrich, St.
Louis, MO, USA) for 30min. Subsequently, the cells were incubated
with primary antibodies overnight at 4 C, washed three times with
PBS, and subsequently incubated with secondary antibodies for
30min at room temperature in the dark. Primary anti-cardiac
troponin T (TNNT2) mouse monoclonal antibodies (13-11, Thermo
Scientiﬁc, Rockford, IL, USA) were used at a dilution of 1:750 in 3%
BSA. The Alexa Fluor 488-conjugated secondary goat anti-mouse
antibody (Life Technologies, Warrington, UK) was diluted to
1:1000 in 3% BSA. Finally, the cells were incubated in NucBlue Fixed
Cell Reagent (Thermo Fisher Scientiﬁc) and ActinRed 555 ReadyP-
robes Reagent (Thermo Fisher Scientiﬁc) in PBS for 30min to
simultaneously stain the nuclei and actin ﬁbers followed by threelular viability (MTT assay) in the presence or absence of fetal bovine albumin (FBS, 10%),
e control (FBSþ, Gluþ, and O2þ) was performed using a one-way ANOVA with the
) overlaid with a bright-ﬁeld image. Cells exposed to the control (FBSþ, Gluþ, and O2þ)
easurement of the PI-stained area. (D, E) Flow cytometry analysis of PI-stained cells.
intensity (E) relative to the control. ***: p < 0.001. (For interpretation of the references
H. Wei et al. / Biochemical and Biophysical Research Communications 520 (2019) 600e605602washes with PBS. The ﬂuorescence images were acquired using a
ﬂuorescence microscope (BZ-X710; KEYENCE, Osaka, Japan).
2.6. Propidium iodide staining
The cells were subjected to propidium iodide staining to assess
the extent of cellular damage. A 1-mg/ml solution of propidium
iodide was diluted to 1:3000 in PBS. After two washes with PBS,
cells were incubated with 200 ml of diluted propidium iodide so-
lution for 30min in the dark. After a single wash with PBS, ﬂuo-
rescence images of the cells were acquired using a ﬂuorescence
microscope (BZ-X710; KEYENCE).
2.7. MTT reagent-based cellular viability assay
The MTT Cell Proliferation Assay Kit (Cayman Chemical Com-
pany, Ann Arbor, MI, USA) was used to quantitatively assess the
viability of H9c2 cells. The cells were incubated with 10 ml of MTT
(37 C; 3 h) in accordance with the manufacturer’s instruction. Af-
ter removing the supernatant, the insoluble formazan crystals were
dissolved in 100 mL of dimethyl sulfoxide solution. The absorbance
in each well was measured with a microplate reader at a wave-
length of 570 nm, and regarded as cellular viability.
2.8. Quantitative real-time PCR
Total RNA was extracted from cells using the High Pure RNA
Isolation Kit (Roche, Indianapolis, IN, USA) and reverse-transcribed
into cDNA using a Verso cDNA Synthesis Kit (Thermo Fisher Sci-
entiﬁc). The expression levels of the target mRNAs were quantiﬁed
using real-time PCR with SYBR Green reagents (Life Technologies)
and primers speciﬁc for TNF-a, IL-1b, IL-8, and caspase 3 mRNAs
and 18S rRNA. The nucleotide sequences of primers are shown in
Table 1. The expression levels of target genes were normalized to
that of 18S rRNA and calculated using the DDCt method. All mea-
surements were performed in triplicate, and three independent
samples were measured per treatment group.
2.9. Contractility of iPS-CMs
Details of themethod used to evaluate iPS-CM contractility were
described elsewhere [4]. Brieﬂy, phase-contrast video microscopic
images of contractions of iPS-CM-derived cardiomyocytes were
recorded using a microscope (BZ-X710; KEYENCE). Discrete two-
dimensional vector ﬁelds of cellular displacement were analyzed
by calculating the displacement vectors D(x,y) in arbitrary units for
every 16-pixel 16-pixel section between the reference frame (i.e.,
ﬁrst frame) and all subsequent frames, using the particle image
velocimetry plugin of Fiji software. A maximum displacement
vector, M(x, y), was deﬁned for every (x, y) pair, and the contrac-
tility value, C, was calculated in arbitrary units as the sum of the
absolute values of the maximum displacement vectors.Table 1
Primers used for quantitative RT-PCR.
Primer Direction Sequence Ref
TNF-a Forward 50-TGTGAGGCGGTTGTGGAAGAGT-30 [5]
Reverse 50-AATGGGGGAAGAGGCAGGTGCA-30
IL-1b Forward 50-AGGCACAAGGCACAACAGGCT-30 [6]
Reverse 50-GGTCCTGGAAGGAGCACTTCATCTG-30
IL-8 Forward 50-AGAAACCACCGGAAGGAACCATCT-30 [7]
Reverse 50-AGAGCTGCAGAAATCAGGAAGGCT-30
Caspase 3 Forward 50-TGTGAGGCGGTTGTGGAAGAGT-30 [8]
Reverse 50-AATGGGGGAAGAGGCAGGTGCA-302.10. Flow cytometry
A 1-mg/ml solution of propidium iodide was diluted to 1:1000
in PBS. After two washes with PBS, the cells were incubated with
the diluted solution for 15min in the dark. Next, the cells were
detached using 0.25% trypsin. After centrifugation, the supernatant
was aspirated, and the cells were reconstituted in 1ml of PBS and
passed through a 30 mm ﬁlter. The samples were then analyzed
using a FACS Aria III system (BD Biosciences, San Jose, CA, USA). The
data were analyzed using Flowing Software (Turku Centre for
Biotechnology, Turku, Finland).
2.11. Statistical analysis
Data from theMTTassay, areas of propidium iodide (PI) staining,
percentages of damaged cells determined by ﬂow cytometry, and
the contractility of iPS-CMs are expressed as means± standard er-
rors of the means. Comparisons between the two groups were
conducted using Student’s t-test. Comparisons between multiple
groups were conducted using a one-way analysis of variance
(ANOVA) with the Bonferroni post-hoc test. PRISM software
(version 5.01; GraphPad Software, La Jolla, CA, USA) was used for
the statistical analysis. Differences were considered signiﬁcant at a
p value< 0.05.
3. Results
3.1. Cellular viability of H9c2 cells under ischemic conditions
We performed an MTT assay to measure cellular viability in the
presence or absence of FBS (10% or 0%), glucose (2 or 0mg/ml), and
oxygen (21% or 2%; Fig. 1A). The mean absorbance in each well, an
indicator of cell viability, was 1.55± 0.20 in the presence of FBS,
glucose, and oxygen (control condition). Conditions of FBS/glucose,
glucose/oxygen, and FBS/glucose/oxygen deprivation reduced the
cell viability to 0.82± 0.05 (p< 0.001 relative to control),
0.59± 0.06 (p< 0.001 relative to control), and 0.59± 0.05 (p< 0.001
relative to control), respectively. Hereafter, the condition with FBS,
glucose, and oxygen was deﬁned as “healthy”, whereas the condi-
tion lacking all three factors was deﬁned as “ischemic.”
3.2. H9c2 cell damage induced by the ischemic condition
Next, we performed PI staining to assess the extent of cell
damage. Although almost no damage was observed under the
control condition, evident damage was observed in the ischemic
group (Fig. 1B and C). The area of PI staining was signiﬁcantly larger
in the ischemic group than in the control group (0.82± 0.06 vs
0.10± 0.03, p< 0.0001).
Flow cytometry also revealed an increase in PI-stained cells
indicative of cell damage. The forward scatter intensity was lower
in the ischemic group than that in the control group (Fig. 1D),
suggesting a decrease in cell size. Moreover, the ratio of PI-positive
cells was higher in the ischemic group (89.0%) than in the control
group (12.4%) (Fig. 1E).
3.3. Induction of cardiomyocyte differentiation from hiPS cells
Next, we differentiated human iPS cells into cardiomyocytes to
develop a model of myocardial infarction. Typically, the hiPS-CMs
exhibited spontaneous contractions at approximately day 14
(supplementary video). Cardiac troponin T (TNNT2) staining to
assess the cardiac differentiation of iPS revealed a typical pattern of
TNNT2 striation in hiPS-CMs, with an approximate sarcomere
length of 1.54 mm (Fig. 2B).
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The viability of hiPS-CMs was measured using the MTT assay.
Notably, higher absorbance was observed in the control group than
in the ischemic group (1.35± 0.07 vs 0.73± 0.03, p< 0.0001;
Fig. 3A). Consistent with the ﬁndings in H9c2 cells, ﬂow cytometry
revealed a reduction in the forward scatter intensity in hiPS-CMs in
the ischemic group, compared with those in the control group
(Fig. 3B). Moreover, the ratio of PI-positive cells was higher in the
ischemic group than in the control group (68.0± 8.7% vs
20.9± 7.5%, p< 0.02; Fig. 3C and D). We further evaluated the
contractility of hiPS-CMs using a displacement vector analysis and
revealed reduced contractility in cells exposed to hypoxia than in
cells exposed to the non-hypoxic control condition (0.23± 0.08 vs
0.77± 0.08, p< 0.005; Fig. 3E and F).Fig. 2. Cardiac differentiation of human induced pluripotent stem (hiPS) cells. (A)
Schematic of the hiPS cell differentiation protocol. StemFit, E8, A, B, and maintenance
indicate the types of media used at each stage. (B) Expression of the cardiac marker
protein cardiac troponin T (TNNT2). Blue: 40 ,6-diamidino-2-phenylindole (DAPI), red:
actin, green: TNNT2. Inset: striated expression of TNNT2, which corresponds to the
sarcomere structure. . (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article.)3.5. Gene expression analysis of inﬂammation-related genes
Finally, we used qPCR to evaluate the expression of genes
related to inﬂammation in hiPSC-CM. Exposure to ischemic con-
ditions increased the expression of TNFa, IL1b, IL6, and IL8 mRNAs
relative to controls (1.28± 0.35, 3.58± 2.14, 1.99± 1.50, and
16.02± 6.25, respectively; Fig. 4A). The DCt values were calculated
to compare gene expression between the control and ischemic
conditions and compared using Student’s t-test in accordance with
themethod of Yuan et al. [9]. Although the differences in DCt values
corresponding to TNFa, IL1b, and IL6 mRNAs did not differ signiﬁ-
cantly between the control and ischemic groups, a signiﬁcant dif-
ference was observed in the DCt values corresponding to IL-8
mRNA (Fig. 4B).
4. Discussion
We developed a model of human ischemic heart disease using
contracting cardiomyocytes differentiated from hiPS cells. This
model is physiologically more similar to the human heart than
models based on conventional cell lines. Currently, two major cell
culture methods are available for mimicking ischemic heart dis-
eases, namely reduced exposure to oxygen and nutrients [10] and
exposure to hydrogen peroxide, which induces cell damage [11]. In
this study, we exposed rat H9c2 cardiomyocytes to oxygen and
glucose concentrations that had been reduced to 2% and 0mg/ml,
respectively, to mimic the conditions of ischemic heart disease.
Subsequently, we found that the same ischemic conditions induced
damage in hiPS-CMs, as indicated by the observed decrease in
cellular viability (Fig. 3A), increase in PI staining (Fig. 3BeD), and
decrease in spontaneous contractility (Fig. 3E and F). In summary,
our results suggest that our low-oxygen/low-glucose protocol in-
duces cardiomyocyte damage that mimics the effects of ischemic
heart disease.
An existing ischemic heart disease model based on mouse iPS-
derived cardiomyocytes is useful due to the more rapid car-
diomyocyte differentiation process relative to that required for
human cells [12]. However, mouse and human cardiomyocytes
exhibit several differences, such as the ﬁring pattern of the action
potential [3] and expression of ion channel genes in the sinus node
[13]. In this study, our use of hiPS-CMs was advantageous because
these cells enabled the development of a model of ischemic heart
disease based on hiPS cells from individual subjects. In a similar
previous study, Mo et al. developed an ischemic heart disease
model based on human iPS-CMs. However, while Mo and col-
leagues focused on the inhibitory effects of microRNA 30e-5p on
the development of hypoxia-induced apoptosis in cardiac cells, we
focused on the pathophysiological conditions associated with
ischemic damage on hiPS-CMs, particularly the changes in
contractility and gene expression.
Acute myocardial infarction, a major cause of death, is partially
attributable to the effects of ischemiaereperfusion injury [14].
Ischemiaereperfusion injury-induced cell damage is caused by
several factors, including peroxidation of the plasma membrane,
opening of the mitochondrial permeability transition pore, activa-
tion of caspases, and subsequent induction of inﬂammation [15].
Kukielka et al. reported that ischemiaereperfusion induced IL8
expression in canine cardiomyocytes, which induced the adhesion
of inﬂammatory neutrophils to the cardiomyocytes [16]. In this
study, we observed increased IL8 mRNA expression in hiPS-CMs
after exposure to the ischemic condition. Although we did not
intentionally include a reperfusion phase in our experimental
procedure, the time lag between the cessation of oxygen/glucose
deprivation and extraction of RNA might have enabled the reox-
ygenation of hiPS-CMs, a main step in the ischemiaereperfusion
Fig. 3. Ischemic conditions damage cardiomyocytes derived from human induced pluripotent stem cells (hiPS-CMs). (A) Comparison of cellular viability (MTT assay). (B, C, and D)
Flow cytometry analysis of propidium iodide (PI)-stained cells. As in Fig. 1D and E, ischemic cells exhibited a reduced forward scatter intensity and increased PI ﬂuorescence,
compared with the control. (D) Percentage of PI-stained cells in the ﬂow cytometry analysis. (E) Analysis of iPS-CMs contractility using ImageJ software. The red and blue vectors
indicate the largest and smallest contractions, respectively. (F) Quantitative analysis of the iPS-CM contractility. *: p < 0.05, **: p < 0.01. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 4. Quantitative real-time PCR-based analysis of inﬂammation marker gene expression. (A) Comparison of mRNA expression levels in cardiomyocytes derived from human
induced pluripotent stem cells (hiPS-CMs) exposed to control and ischemic conditions. TNFa: tumor necrosis factor-alpha. Bars indicate the standard errors of the means. (B)
Statistical analysis of the gene expression DCt values from (A). *: p < 0.05.
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crease in IL8 expression is an important outcome of our study.
Although our hiPS-CMmodel advantageously mimicked human
ischemic heart disease, some limitations should be noted. For
example, our model did not include important factors such as
leukocyte-induced tissue damage and complement system activa-
tion. Moreover, the percentage of differentiated cardiomyocytes in
the model requires optimization. Nevertheless, our newly devel-
oped model of human ischemic heart disease is relatively simpleand easy to reproduce and can be used in applications, such as drug
screening using patient-derived iPS cells. Our model can also
further elucidate the mechanism underlying ischemic heart
diseases.
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